Current Report Filing (8-k)
December 16 2021 - 03:46PM
Edgar (US Regulatory)
0001348362false00013483622021-12-152021-12-15iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported)
December 15,
2021
LEXARIA BIOSCIENCE
CORP.
|
(Exact name of registrant as specified in its charter)
|
Nevada
|
|
000-52138
|
|
20-2000871
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
100 – 740 McCurdy Road, Kelowna, BC Canada
|
|
V1X 2P7
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code
(250)
765-6424
______________________________________________
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.001 per share
Warrants to Purchase Common Stock
|
|
LEXX
LEXXW
|
|
The Nasdaq Capital Market
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 1.01
|
Entry into a Material Definitive Agreement
|
On December 15, 2021, Lexaria Bioscience Corp.
(“Lexaria”), entered into a Media Buys Agreement
as further supplemented by the terms and conditions for payment of
media buys via securities (the “Agreement”), with
SRAX, Inc. (“SRAX”). Pursuant to the Agreement,
SRAX will act on behalf of Lexaria to deliver paid media across
multiple platforms and will be authorized to engage third party
media companies in the provision of these services (the
“Services”). The consideration for the Services is
$1,200,000 pursuant to which SRAX has agreed to settle through the
receipt of 224,299 Lexaria common shares being issued at a deemed
price of $5.35 per share (the “Shares”). The
Shares will be issued as restricted securities and will bear the
applicable legends required by Canadian and US securities laws.
Item 3.02
|
Unregistered Sales of Equity Securities
|
On December 16, 2021, Lexaria issued to SRAX, pursuant to the terms
of the Agreement, 224,299 Shares at a deemed price of $5.35 per
share for deemed aggregate consideration of $1,200,000. The Shares
have not been registered under the Securities Act of 1933, as
amended (the “Securities Act”) or any state
securities laws. The issuance of the Shares will be in reliance on
the exemptions from registration provided by Section 4(a)(2) under
the Securities Act.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
LEXARIA BIOSCIENCE CORP.
|
|
|
|
/s/ Chris Bunka
|
|
Chris Bunka
|
|
CEO, Principal Executive Officer
|
|
|
|
Date: December 16, 2021
|
|
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Jun 2022 to Jul 2022
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Jul 2021 to Jul 2022